SUMMARY: Multiple Myeloma (MM) is a clonal disorder of plasma cells in the bone marrow and the American Cancer Society estimates that in the United States, 36,000 new cases will be diagnosed in 2026, and 10,850 patients are expected to die of the disease. Multiple Myeloma is a disease of the elderly, with a median age at diagnosis of 69 years and characterized by intrinsic clonal heterogeneity. Almost all patients eventually will relapse, and patients with a high-risk cytogenetic profile, extramedullary disease or refractory disease have the worst outcomes.
Modern therapies,including Proteasome Inhibitors, Immunomodulatory drugs, and anti-CD38 antibodies, have extended survival to nearly a decade. However, patients whose disease becomes resistant to these treatments face poor outcomes with a median survival of less than 1 year. There is a critical need for novel, effective therapies with new mechanisms of action
B-cell Maturation Antigen (BCMA) is a member of the Tumor Necrosis Factor superfamily of proteins. It is a transmembrane signaling protein primarily expressed by malignant and normal plasma cells and some mature B cells. BCMA is involved in JNK and NF-kB signaling pathways that induce B-cell development and autoimmune responses.
CAR T-Cell Therapy & BCMA Targeting
Anti-BCMA CAR T-Cell Therapy is a type of immunotherapy and consists of T cells collected from the patient’s blood in a leukapheresis procedure. These T cells are then stimulated by treating with interleukin 2 (IL-2) and anti-CD3 antibodies in vitro, so that they will actively proliferate and expand to large numbers. These T cells are then genetically engineered to produce special receptors on their surface called Chimeric Antigen Receptors (CAR), by transducing with a gene encoding the engineered CAR, via a retroviral vector such as lentiviral vector. These reprogrammed cytotoxic T cells with the Chimeric Antigen Receptors on their surface are now able to recognize a specific antigen such as BCMA on tumor cells. These genetically engineered and reprogrammed CAR T-cells are grown in the lab and are then infused into the patient. These cells in turn proliferate in the patient’s body and the engineered receptor on the cell surface help recognize and kill cancer cells that expresses that specific antigen such as BCMA. The patient undergoes lymphodepletion chemotherapy with Fludarabine and Cytoxan prior to the introduction of the engineered CAR T-cells to upregulate cytokine production and promote the expansion of the engineered CAR T-cells.
Ciltacabtagene autoleucel (Cilta-cel; CARVYKTI®), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to Lenalidomide.
CARTITUDE-4 Study
CARTITUDE-4 is an ongoing open-label, multicenter, randomized Phase III trial conducted to compare Cilta-cel with the physician’s choice of either of two highly effective standard-of-care therapies, in patients with Lenalidomide-refractory multiple myeloma after one to three lines of therapy. In this study a total of 419 eligible patients (N=419) were randomly assigned in a 1:1 ratio to receive either one of the standard-of-care physicians choice of PVd-Pomalidomide, Bortezomib, and Dexamethasone, DPd-Daratumumab, Pomalidomide, and Dexamethasone (N=211) or a single infusion of Cilta-cel administered after the physician’s choice of bridging therapy with PVd or DPd (N=208). In the standard-of-care group, DPd was administered in 28-day cycles and PVd in 21-day cycles until disease progression. Patients in the Cilta-cel group underwent apheresis, followed by at least one bridging therapy cycle, with the number of cycles based on patient clinical status and Cilta-cel manufacturing time, and lymphodepletion with Cyclophosphamide 300 mg/m2 IV and Fludarabine 30 mg/m2 IV daily for 3 days. Patients then received a single Cilta-cel infusion at a target dose of 0.75X106 CAR-positive T cells/kg of body weight 5-7 days after the initiation of lymphodepletion. The median age was 61 yrs, median time from diagnosis was 3.2 years, about 60% of patients had high risk cytogenetic abnormalities and all patients had received 1-3 previous lines of treatment. In the Cilta-cel group, 14.4% had triple-class drug resistance and 24.0% had resistance to anti-CD38 antibody. The Primary outcome was Progression Free Survival and Secondary outcomes sequentially tested included Complete Response (CR) or better, Overall Response Rate (ORR), Minimal Residual Disease (MRD) negativity, and Overall Survival (OS).
In the first interim analysis, a single Cilta-cel infusion resulted in a lower risk of disease progression or death, as well as rapid and deep responses, compared to standard therapies in Lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies
The researchers in this publication reported a prespecified second interim analysis of OS and an updated analysis of PFS in the intention-to-treat population. New data from the CARTITUDE-4 study highlight the significant clinical benefits of Cilta-cel in patients with Lenalidomide-refractory multiple myeloma who have received one to three prior lines of therapy.
Key Efficacy Findings
With a median follow-up of nearly 34 months patients receiving Cilta-cel experienced substantially longer disease control. Median PFS was not reached, compared with 11.8 months for those on standard therapy, representing a 71% reduction in the risk of progression or death.
Overall Survival outcomes also favored Cilta-cel. While median OS was not reached in either group, treatment with Cilta-cel led to a 45% reduction in the risk of death, a statistically significant improvement.
At 30 months, approximately 59% of Cilta-cel patients were alive and progression-free vs 26% with standard care. Around 66% remained treatment-free after a single infusion.
Cilta-cel achieved higher rates of sustained MRD negativity, indicating deeper and more durable responses.
Safety Overview
Safety outcomes were evaluated in 208 patients per group. Grade 3 Adverse Events (AEs) were 14% with Cilta-cel versus 37% with standard of care and Grade 4 AEs were 75% with Cilta-cel versus 56% with standard of care and was most commonly neutropenia in both groups. Treatment-Related Deaths was 3% with Cilta-cel and 2% with standard therapy. Most were linked to infections.
Why This Matters
CARTITUDE-4 is the first Phase 3 trial to demonstrate a significant Overall Survival benefit with CAR T-cell therapy in multiple myeloma. These findings reinforce the potential of Cilta-cel as an earlier-line treatment option. Even as newer therapies continue to emerge, Cilta-cel shows competitive, and in many cases superior outcomes, including notably higher MRD-negative response rates compared with other modern regimens.
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. Einsele H, San-Miguel J, Dhakal B et al. The Lancet Oncology, 2026;27:254-268
